Meridian Life Science, Inc. is a world leader in the use of the Baculovirus Insect Cell Expression Vector System for the production of recombinant proteins such as Virus-Like Particles for vaccine products.

Baculovirus Expression Vector System:

Case Study in BEVS:

Parvovirus B19 Vaccine:

Meridian Life Science has manufactured, and subsequently licensed, a recombinant Parvovirus B19 vaccine under a contract from the National Heart Lung and Blood Institute of the National Institutes of Health. The vaccine was manufactured according to cGMP in Meridian Life Science's fully qualified Spodoptera Frugiperda (Sf9) insect cell line and is now in Phase I/II safety/efficacy trials.  The vaccine consists of two viral proteins (VP1 and VP2) in separate Baculovirus vectors that are co-infected at the correct MOI's into Sf9 cells and that, upon expression, self assemble into immunogenic virus-like particles.  Meridian Life Science has a validated cGMP vialing line for this product of up to 2,500 vials.